Biogen Idec has retained Hanold Associates

Biogen Idec (NASDAQ: BIIB) has teamed up with Hanold Associates to lead the search for their Head of Talent Acquisition in Research and Development Division. Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients’ worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen is the world’s oldest independent biotechnology company and a Fortune 500 company with more than $5 billion in annual revenues. Patients worldwide benefit from their leading multiple sclerosis therapies.